Teva Opens New Sterile Plant in Hungary - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Teva Opens New Sterile Plant in Hungary


ePT--the Electronic Newsletter of Pharmaceutical Technology

Teva has invested $110 million in a new sterile plant in Gödöllő, Hungary. With 15,000 m2 of production area and modular building, as well as an annual production capacity of 160–200 million units of injection products in six production lines, Teva hopes the plant will strengthen the company’s role in Hungarian drug production.

At the opening ceremony, which took place on Oct. 2, 2012, Jeremy Levin, president and CEO of Teva, highlighted the company’s commitment to quality drug production and its Hungarian employees. "This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital."

According to a press statement, Teva’s new plant is not only one of the biggest sterile pharmaceutical plants, but also one of the most flexible ones in the world. The large production potential and flexibility means that the company will be able to supply patients in more than 70 countries, mainly in the US, Europe, and Far East.

Teva has been operating in Hungary since 1993 and employs more than 3500 people.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here